Wire · opportunities
Samsung Biologics Acquires PolyPeptide Group for Obesity Drugs
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 July 2026 · Fusion42 review
Samsung Biologics is acquiring Swiss CDMO PolyPeptide Group for $1.46 billion to expand from antibody manufacturing into peptide production, capturing capacity for GLP-1 obesity and diabetes drugs. The deal adds six manufacturing facilities across Europe, the US and India, plus 1,500 skilled staff and existing pharma contracts.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you supply raw materials, purification systems or analytics to peptide manufacturers, your addressable market just consolidated and got funded. Samsung now has six facilities and $1.46 billion committed to GLP-1 production—call them before they spec their suppliers.
◆ Coverage
1 source · 20 Jul 2026
◆ Related on Wire
◆ Topics